PSMA therapy in Germany
PSMA-targeted therapy for prostate cancer: from accurate diagnosis to innovative treatment
PSMA therapy is a breakthrough method of radionuclide treatment of metastatic prostate cancer, especially effective in castration-resistant forms. The RheinRegio Klinik Zentrum uses advanced technology using lutetium-177 (¹⁷⁷Lu-PSMA), which precisely targets cancer cells while minimizing the impact on healthy tissue.
What is PSMA therapy?
PSMA (prostate-specific membrane antigen) is a protein that is produced in large quantities by prostate cancer cells in 90% of cases. The method is based on targeted effects:
- The radiopharmaceutical (¹⁷⁷Lu-PSMA) binds to PSMA antigens.
- Lutetium-177 beta radiation destroys tumors and metastases.
Advantages over chemotherapy:
- Targeted effect only on cancer cells.
- Fewer side effects (no systemic damage).
- Effective in resistant forms of prostate cancer.
Indications for PSMA therapy
The method is used when:
- Metastatic prostate cancer (bones, lymph nodes, liver).
- Castration-resistant adenocarcinoma (CRPC).
- Relapses after hormonal/chemotherapy.
- Ineffectiveness of other methods.
Contraindications:
- Severe renal failure.
- Low PSMA expression (confirmed by PET-CT).
Each direction is supervised by advanced oncologists.
Find out the cost of treatment
To find out the approximate cost of treatment, answer a few questions and we will contact you!
Diagnosis before PSMA therapy
At RheinRegio Klinik Zentrum we carry out:
- PSMA-PET/CT – detection of foci with high antigen expression.
- Biopsy + histology – confirmation of adenocarcinoma.
- Blood tests (PSA, creatinine, hemoglobin).
- Bone scintigraphy – assessment of bone metastases.
How is the treatment carried out?
- Preparation:
- Discontinuation of certain medications (eg, bisphosphonates).
- Hydration (to protect the kidneys).
- Administration of the drug:
- Intravenous infusion of ¹⁷⁷Lu-PSMA (5-7 minutes).
- Course: 4-6 cycles with an interval of 6-8 weeks.
- Monitoring:
- PSA monitoring, MRI/PET-CT after 2-3 cycles.
Side effects (usually mild):
- Dry mouth, fatigue.
- Temporary decrease in platelet/leukocyte levels.
The effectiveness of PSMA therapy
- A decrease in PSA by 50% or more – in 60-70% of patients.
- Reduction of metastases – in 40-50% of cases.
- Improved quality of life – reduced pain, increased activity.
PSMA therapy is a chance for patients with advanced prostate cancer when other methods are powerless. The RheinRegio Klinik Zentrum uses the most modern protocols approved in the EU.
Find out if this method is right for you – sign up for a consultation!
Key advantages of the clinic:
- Accurate PSMA-PET/CT diagnostics.
- Treatment without pain and hospitalization (outpatient).
- 100% confidentiality and support in Russian
Our clinics
The association of clinics RheinRegio Klinik Zentrum offers the organization of lymphoma treatment in Germany without intermediaries, providing access to the country’s leading oncology clinics. We combine advanced techniques, an individual approach and the highest level of medical care, giving hope even in difficult cases.
Why RheinRegio Klinik Zentrum?
- Specialists with international experience – oncologists, nuclear doctors.
- The latest radiopharmaceuticals (¹⁷⁷Lu-PSMA, ²²⁵Ac-PSMA).
- Individual regimens – combination with hormone therapy, immunotherapy.
- Full support – from diagnosis to rehabilitation.
